Japan-based Takeda Pharmaceutical Company, through its Indian subsidiary Takeda Biopharmaceuticals India, and Dr. Reddy’s ...
US health tech company Massive Bio has appointed international business development consultancy Intralink to support its ...
Australia's Monash University has collaboratd with Weill Cornell Medicine, Cornell University’s academic medical institution, ...
HSA Extends Partnerships to Speed Access to Health Innovations Across Key Markets in Africa, Malaysia and Saudi Arabia ...
Swiss firm Tenthpin expands footprint in India with AI, IoMT-based Centre for Life Sciences Innovation Hub in Bengaluru ...
Under the terms of the agreement, China-based WuXi XDC will grant Ona Therapeutics an exclusive global license to its ...
To enable faster, easier and more flexible RNA-to-cDNA synthesis, Thermo Fisher Scientific has introduced Invitrogen™ ...
All deal values reflect company disclosures. Where parties have not disclosed terms, they are reported as undisclosed. No ...
Japan’s MHLW has approved Lundbeck’s Vyepti for prevention of migraine attacks in adults, marking the company’s first planned launch as Marketing Authorisation holder in Japan.
IASO Bio has received FDA IND clearance for IASO208, the first China-originated lentiviral vector-based in vivo CAR-T therapy to reach this regulatory milestone.
Israeli medical technology company P-Cure and Indian healthcare company ARISTION Proton Centre have announced the signing of ...
Japan has approved the LEQEMBI Pen subcutaneous autoinjector for early Alzheimer’s disease, enabling once-weekly administration at home by patients or care partners.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results